Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptormutated advanced non-small cell lung cancer

Background: Response rates of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) and 40 mg OD] are similar to those of the recommended dose of 80 mg OD, but there is a lack of real-world evidence on the e...

Full description

Bibliographic Details

Main Authors:	Mau, Ern Poh, Balakrishnan, Sivasubramaniam, Tan, Sin Nee, Zainal Abidin, Muhammad 'Adil, Liam, Chong-Kin, Tan, Jiunn Liang, Pang, Yong Kek, Alaga, Arvindran, Tho, Lye Mun, How, Soon Hin
Format:	Article
Language:	en
Published:	AME Publishing Company 2024
Subjects:	RC270 Neoplasms. Tumors. Oncology-Cancer and Other Malignant Neoplasms-Therapeutics
Online Access:	http://irep.iium.edu.my/113631/2/113631_Real-world%20efficacy%20of%20low%20dose%20osimertinib.pdf http://irep.iium.edu.my/113631/ https://tlcr.amegroups.org/article/view/88599/html
Tags:	Add Tag No Tags, Be the first to tag this record!